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INTRODUCTION
Although radiofrequency catheter ablation (RFCA) for atrial fi-
brillation (AF) is an effective strategy for rhythm control, there 
remains a substantial recurrence rate.1-3 The majority of AF cas-
es are triggered in patients with paroxysmal AF (PAF) derived 
from pulmonary veins (PVs), although 10–30% of PAF patients 
and the majority of patients with persistent AF (PeAF) have 
non-PV triggers.1,4-6 Therefore, post-procedural detection and 
elimination of non-PV triggers might result in a better clinical 
outcome. Testing for immediate recurrence of AF after cardio-
version is the common method for the detection of AF trig-
gers.7,8 However, a post-procedural test for immediate recur-
rence of AF requires time, isoproterenol infusion,6 sedation, 
and electrical cardioversion. Moreover, repetitive electrical car-
dioversion may increase the risk of peri-procedural stroke in 
high-risk patients.9 Therefore, the clinical value of a post-proce-
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dural test for immediate recurrence of AF and additional abla-
tion targeting remaining non-PV foci has not been clearly de-
termined. With the development of a three-dimensional (3D)-
electroanatomical software mapping system, the mapping and 
ablation of frequent atrial premature beats (APBs) has become 
relatively fast and accurate. Therefore, we hypothesized that 
non-PV–origin APBs may contribute to AF recurrence after 
catheter ablation. We defined the provocation of immediate re-
currence of APBs (IRAPBs) as the detection of post-procedural 
frequent APBs (≥6 beats per minute) after electrical cardiover-
sion under isoproterenol infusion (5 μg/min). The purposes of 
this study were to explore whether post-procedural IRAPB 
provocation and additional ablation for mappable frequent 
APBs affect the clinical outcome of AF ablation and whether 
IRAPB provocation lengthens procedure time or increases the 
complication rate. We also tested whether the type of induced 
tachyarrhythmias [AF or atrial tachycardia (AT)] and the pres-
ence of IRAPB are risk factors for clinical recurrence of AF after 
catheter ablation.
MATERIALS AND METHODS
Study population
The study protocol adhered to the Declaration of Helsinki and 
was approved by the Institutional Review Board of Yonsei Uni-
versity Health System. All patients provided written informed 
consent. This study was a single-center retrospective compari-
son study, and patients were matched 1:1 by age, sex, and AF 
type. The study included patients with AF (76.5% males; 
57.4±11.1 years old) who underwent RFCA between March 2011 
and December 2012. The exclusion criteria were as follows: 1) 
permanent AF refractory to electrical cardioversion; 2) AF with 
valvular disease (>grade II); 3) associated structural heart dis-
ease other than left ventricular hypertrophy; and 4) prior AF 
ablation. IRAPB provocation tests were conducted in 100 con-
secutive patients, who were compared with 100 age-, sex-, and 
AF-type–matched patients who completed ablation without 
any induction or mapping test (No-Test group) (Fig. 1). Among 
them, 67.0% of patients had PAF, and 33.0% had PeAF. 3D spiral 
computerized tomography (CT) scans (64 Channel, Light 
Speed Volume CT, Philips, Brilliance 63, the Netherlands) were 
performed to visually define atrial and PV anatomy in all pa-
tients. The presence of a left atrial (LA) thrombus was excluded 
by trans-esophageal echocardiography. All antiarrhythmic 
drugs were discontinued for a period corresponding to at least 
five half-lives. In total, 58 patients (29.0%) were taking amioda-
rone, which was discontinued for at least 4 weeks prior to the 
procedure. Anticoagulation therapy was maintained before 
catheter ablation.
Electrophysiologic mapping and radiofrequency  
catheter ablation
Intracardiac electrograms were recorded using the Prucka Car-
dio LabTM electrophysiology system (General Electric Health 
Care System Inc., Milwaukee, WI, USA), and catheter ablation 
was performed in all patients using 3D electroanatomical map-
ping (St. Jude Medical Inc., Minnetonka, MN, USA) merged 
with 3D spiral CT. We used an open irrigated-tip catheter (Cel-
sius, Johnson & Johnson Inc., Diamond Bar, CA, USA; Coolflex, 
Fig. 1. Diagram of study protocol. We compared the clinical efficacy of post-procedural provocation for immediate recurrence of atrial premature beats 
(IRAPBs) under isoproterenol and additional ablation targeting these APBs (n=100) with 100 age-, sex-, and AF-type–matched patients who completed the 
procedure without an induction test (No-Test group). CL, cycle length; RFCA, radiofrequency catheter ablation; AF, atrial fibrillation; AT, atrial tachycardia.
Age, sex, and AF type matching
AF with RFCA (n=200)
Post-RFCA IRAPB provocation group
AF/AT induction & cardioversion (n=100)
Internal cardioversion (n=100)
IRAPB (+) (n=33)
Additional ablation
IRAPB (-) (n=67)
No Test (n=100)
Post-RFCA No-Test group
Rapid atrial pacing CL 250–150 ms 
Isoproterenol 5 μg/min IV (>3 min)
Stop isoproterenol
Waiting for 10 min
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St. Jude Medical Inc., Minnetonka, MN, USA; 30–35 W; 47°C) to 
deliver RF energy for ablation (Stockert generator, Biosense 
Webster Inc.; Diamond Bar, CA, USA). All patients initially un-
derwent circumferential PV isolation and bi-directional block 
of the cavo-tricuspid isthmus. For patients with PeAF, we added 
the roof line, posterior inferior line, and anterior line10 as a stan-
dard lesion set. All procedures were conducted by two opera-
tors with over 10 years of experience.
Post-procedural protocol for IRAPB provocation
Fig. 1 summarizes the study protocol. After a standard proce-
dure, AF or AT was induced by 10-second high-current burst 
pacing (10 mA, pulse width 5 ms, Bloom Associates, Denver, 
CO, USA) from the high right atrial (RA) electrodes. This com-
menced at a pacing cycle length of 250 ms and was gradually 
reduced to 120 ms as previously described (Fig. 2A).11 We initi-
ated isoproterenol (5 μg/min) infusion for at least 3 minutes be-
fore induction and maintained this for 3 minutes after the in-
duction of AF or AT. Then, internal cardioversion was performed 
by utilizing biphasic shock (2–15 J) with R wave synchroniza-
tion (Lifepak12, Physiocontrol Ltd., Redmond, WA, USA) using 
an anodal decapolar catheter (WOVEN diagnostic catheter, 
Bard Electrophysiology, Lowell, MA, USA) in the RA and a cath-
odal duo-decapolar catheter (St. Jude Medical Inc., Minneton-
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HRA 1~0 (-)
CS 1~10 (+)
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LAO 35º
Fig. 2. (A) Inducibility test by high-current HRA pacing for 10 sec. AF or AT maintenance longer than 3 min was considered positive inducibility. (B) Cathe-
ter position for mapping and cardioversion. For the IRAPB test, we delivered internal cardioversion shock from HRA to CS. (C) An example of IRAPB after 
cardioversion under isoproterenol infusion. CS, coronary sinus; HRA, high right atrium; LAO, left anterior oblique view; RV, right ventricle; AF, atrial fibrilla-
tion; AT, atrial tachycardia; IRAPB, immediate recurrence of atrial premature beat.
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ka, MN, USA) in the coronary sinus (CS) (Fig. 2B). After suc-
cessful electrical cardioversion, we stopped isoproterenol 
infusion and waited for 10 minutes to map IRAPBs or immedi-
ate recurrence of AF originating from the non-PV foci (Fig. 2C). 
All mappable IRAPBs (≥6/min) or APBs triggering AF were 
mapped and ablated during the waiting period in the IRAPB 
provocation group. If AF recurred immediately (8 of 100) or 
during the mapping of IRAPBs (5 of 100) after cardioversion, we 
repeated internal cardioversion and attempted to ablate all 
mappable frequent IRAPBs.
Post-ablation follow-up
Patients were discharged without any anti-arrhythmic drugs 
and asked to visit the outpatient clinic at 1, 3, 6, and 12 months 
after RFCA and every 6 months thereafter for follow-up. Elec-
trocardiography (ECG) was performed at each visit or anytime 
the patient reported palpitations. A Holter ECG (24-hour or 48-
hour) and/or event recorder was evaluated at 3, 6, and 12 
months after RFCA and every 6 months thereafter for at least 2 
years, according to the 2012 HRS/EHRA/ECAS Expert Consen-
sus Statement guidelines.12 We defined recurrence of AF as any 
episode of AF or AT with a duration of at least 30 sec.13 If any ECG 
documented an AF episode within the 3-month blanking peri-
od during follow-up, the patient was diagnosed with an early 
recurrence. Any AF recurrence thereafter was diagnosed as 
clinical recurrence,13 and antiarrhythmic medications were 
prescribed.
Data analyses
We compared clinical and electroanatomical markers in pa-
tients who experienced recurrence of AF with those in pa-
tients who remained in sinus rhythm. Data are expressed as 
mean±standard deviation. Statistical significance of the com-
parisons was assessed using Student’s t-test, Fisher’s exact test, 
and Kaplan-Meier analysis. A p-value of <0.05 was considered 
statistically significant.
RESULTS
Mapping and ablation of post-procedural IRAPBs 
Fig. 1 summarizes the study protocol. Among the 100 patients 
in the IRAPB provocation group (70 PAF, 30 PeAF), we mapped 
and ablated IRAPBs in 33 patients, and 67 did not show post-
procedural IRAPB after stopping the isoproterenol infusion 
(Table 1). The patients who tested positive for IRAPB had a 
higher CHADS2 score (p=0.003), higher prevalence of previous 
stroke/transient ischemic attack (p=0.002), higher frequency of 
sinus node dysfunction (p=0.025), and a larger left atrial volume 
index (LAVI; p<0.001) than those who did not. Fig. 3A shows the 
44 sites for IRAPBs and additional ablation in 33 patients with 
positive IRAPB, with locations as follows: superior vena cava 
Table 1. Characteristics of IRAPB Provocation Group Depending on the Presence of IRAPBs and Additional Ablation
Variables IRAPB (+) (n=33) IRAPB (-) (n=67) p value
Male, n (%) 22 (66.7) 54 (80.6) 0.128
Patient age (yrs) 57.6±9.5 56.6±11.7 0.692
PAF, n (%) 20 (60.6) 50 (74.6) 0.153
BMI (kg/m2) 25.0±3.0 24.1±2.6 0.183
CHADS2 score, n (%) 1.1±1.1 0.6±0.8 0.003
Congestive heart failure 0 (0.0) 2 (3.0) 0.321
Hypertension 17 (51.5) 26 (38.8) 0.232
Age ≥75 yrs 1 (3.0) 1 (1.5) 0.610
Diabetes 6 (18.2) 5 (7.5) 0.109
Stroke/TIA 7 (21.2) 2 (3.0) 0.002
Sinus node dysfunction, n (%) 5 (15.2) 2 (3.0) 0.025
LA diameter (mm) 41.1±4.1 39.1±4.8 0.052
LA volume index (mL/m2) 36.2±11.2 28.2±8.5 <0.001
LV EF (%) 64.5±6.0 64.1±8.1 0.806
E/Em 9.7±3.6 8.9±3.0 0.278
Procedure time (min) 201.0±34.8 174.3±30.7 0.001
Ablation time (sec) 5280.0±1470.9 4617.0±1304.4 0.038
Procedure-related complications, n (%) 1 (3.0) 3 (4.5) 0.732
Follow-up duration (months) 17.4±5.7 18.1±7.4 0.643
Early recurrence rates (%) 36.4 10.4 0.002
Clinical Recurrence rates (%) 27.3 9.0 0.016
BMI, body mass index; E/Em, ratio of early mitral inflow peak velocity and Doppler-derived early diastolic mitral annular velocity; IRAPB, immediate recurrence 
of atrial premature beats after cardioversion; LA, left atrium; LV EF, left ventricular ejection fraction; PAF, paroxysmal atrial fibrillation; TIA, transient ischemic at-
tack.
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(n=12), interatrial septum (n=11), CS ostium (n=10), ligament 
of Marshall (n=6), crista terminalis (n=3), and LA posterior wall 
(n=2, one PAF and one PeAF). The RA volume index of the pa-
tients with RA-origin IRAPB (21.1±5.6 mL/m2) tended to be 
greater than those with LA origin IRAPB (19.5±4.6 mL/m2) with-
out statistical significance (p=0.462). In patients with frequent 
and uni-focal IRAPBs, 3D-electroanatomical mapping was uti-
lized for accurate mapping of non-PV foci or recovered conduc-
tion at linear ablation sites (Fig. 3B). The patients who under-
went IRAPB ablation required a significantly longer procedure 
time (p=0.001) and ablation time (p=0.038) than those without 
IRAPB (Table 1). However, additional ablation for IRAPBs did 
not increase the procedure-related complication rate (p=0.732).
Presence of post-procedural IRAPBs is associated 
with higher clinical recurrence rate
During 18.0±6.6 months of follow-up, the early recurrence rate 
and clinical recurrence rate were 19% and 15%, respectively, for 
the IRAPB-provocation group. Among 51 patients with positive 
post-procedural inducibility before isoproterenol infusion, 
there was no significant difference in recurrence rates with re-
spect to the type of induced atrial tachyarrhythmias (AF vs. AT; 
p=0.694) (Table 2). However, the patients with positive IRAPB 
showed a significantly higher early recurrence rate (36.4% vs. 
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Fig. 3. (A) Locations of post-procedural IRAPBs and additional ablation sites (black circles). White circles indicate the standard ablation sites for PAF. (B)
Mapping and ablation of post-procedural IRAPB utilizing 3D activation map. Quick activation mapping by multipolar catheter revealed non-PV foci locat-
ed on LA posterior wall (white dots) and conduction gap at posterior inferior linear ablation site. We eliminated IRAPBs and ablation gap on posterior infe-
rior line concomitantly. (C) Kaplan-Meier curve for AF-free survival comparing patients with post-procedural IRAPBs to those without IRAPBs. (D) Kaplan-
Meier graph of AF-free survival comparing the IRAPB provocation group to the No-Test group. IRAPBs, immediate recurrence of atrial premature beats; 
3D, three-dimensional; PV, pulmonary vein; LA, left atrial; AF, atrial fibrillation; PAF, paroxysmal AF.
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10.4%; p=0.002) and clinical recurrence rate (27.3% vs. 9.0%; 
p=0.016) than those with negative IRAPBs, despite additional 
ablation and a longer procedure time (p=0.001) (Table 1). On 
multivariate logistic regression analysis, IRAPB (β=1.398; odds 
ratio=4.046; 95% confidence interval 1.14–14.39; p=0.031) was 
independently associated with clinical recurrence after RFCA 
of AF (Table 3). Table 3 also shows that the type of induced atrial 
tachyarrhythmias, AT (p=0.308) or AF (p=0.422), was not asso-
ciated with clinical recurrence. Kaplan-Meier analysis showed 
consistently worse clinical outcome in patients with positive 
IRAPBs after the procedure (log rank, p=0.007) (Fig. 3C).
IRAPB provocation and ablation results in better  
clinical outcome of AF ablation
We compared patient characteristics, procedure time, proce-
dure-related complication rate, and clinical outcome between 
the patients with IRAPB provocation and age-, sex-, and AF-
type–matched patients who completed the procedure without 
an induction test (No-Test group) (Table 4). The baseline char-
acteristics, LA diameter (p=0.187), LAVI (p=0.105), procedure 
times (p=0.540), ablation times (p=0.848), and procedure-relat-
ed complication rates (p=0.702), were not significantly different 
between the two groups. However, the clinical recurrence rate 
(15.0% vs. 28.0%; p=0.025) was significantly lower in the IRAPB 
provocation and ablation group than in the No-Test group. Ka-
plan-Meier AF-free survival analysis indicated a consistently 
better clinical outcome in the IRAPB provocation group than in 
the No-Test group (log rank, p=0.038) (Fig. 3D).
DISCUSSION
In the current study, we reported the potential usefulness of 
post-procedural IRAPB provocation and additional ablation 
during AF catheter ablation. The patients who showed post-pro-
cedural IRAPB under isoproterenol had a clearly higher clinical 
recurrence rate of AF than those without IRAPB. However, clini-
cal outcome was better in patients with routine post-procedural 
IRAPB provocation and additional ablation than in those who 
completed the procedure without an induction test. This study 
revealed the importance of remaining non-PV foci as a mecha-
nism of recurrence after AF catheter ablation. Therefore, a fur-
ther prospective study with a larger number of patients is war-
ranted to prove whether routine IRAPB provocation facilitates 
an improved clinical outcome of AF catheter ablation. 
Role of post-procedural detection of AF triggers  
or substrate
AF is generally a progressive disease, and the mechanism for 
generation of AF is not yet fully understood.1,14 Coumel15,16 sug-
gested that trigger factors or trigger foci initiate AF, and arrhyth-
mic substrate leads to its persistence. In this study, we explored 
the clinical significance of post-procedural tests for AF triggers 
or IRAPB. It is known that 70–90% of AF triggers exist around 
PVs in patients with PAF; however, non-PV foci are more com-
mon in those with PeAF.4-6 Generally, PV isolation at the level of 
the PV antrum is a cornerstone of catheter ablation for AF.17-19 
In this study, by isolating PVs during the procedure, all post-
Table 2. Clinical Outcomes Depending on the Type of Post-Procedural Atrial Tachyarrhythmias (AT/AF) Induced by High-Current Rapid Atrial Pacing 
Variables AT induction (n=35) AF induction (n=16) p value
Follow-up duration (month) 18.2±6.1 17.3±4.9 0.625
Early recurrence rates (%) 28.6 31.3 0.849
Clinical recurrence rates (%) 20.0 25.0 0.694
AF, atrial fibrillation; AT, atrial tachycardia.
Table 3. Factors Associated with Clinical Recurrence after Radiofrequency Catheter Ablation (Logistic Regression Analyses)
Variables
Univariate analysis Multivariate analysis
OR 95% CI p value OR 95% CI p value
PAF 0.590 0.19–1.84 0.363 0.986 0.26–3.74 0.983
Male 1.312 0.34–5.10 0.695 1.373 0.29–6.56 0.691
Age (yrs) 1.014 0.96–1.07 0.596 1.001 0.94–1.07 0.967
Diabetes 4.052 1.02–16.13 0.047 3.205 0.71–14.41 0.129
Pre-RFCA LA volume index (mL/m2) 1.046 0.99–1.11 0.132
Pre-RFCA LV EF (%) 1.044 0.96–1.13 0.304 1.018 0.93–1.12 0.711
Pre-RFCA E/Em 1.009 0.85–1.21 0.919 0.983 0.79–1.22 0.878
AT or AF induction (+) 3.094 0.91–10.49 0.070
AT induction (+) 1.781 0.59–5.41 0.308
AF induction (+) 1.625 0.50–5.31 0.422
IRAPB (+) 3.812 1.22–11.87 0.021 4.046 1.14–14.39 0.031
AF, atrial fibrillation; AT, atrial tachycardia; CI, confidence interval; E/Em, ratio of early mitral inflow peak velocity and Doppler-derived early diastolic mitral annu-
lar velocity; IRAPB, immediate recurrence of atrial premature beats; LA, left atrial; LV EF, left ventricular ejection fraction; OR, odds ratio; PAF, paroxysmal atrial 
fibrillation; RFCA, radiofrequency catheter ablation.
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procedural IRAPBs arose from non-PV foci. Although the pres-
ence of IRAPBs from these non-PV foci clearly worsened the 
clinical outcome of AF ablation, additional ablation targeting 
IRAPB might result in a lower recurrence rate than that of the 
No-Test group. Therefore, remaining non-PV–origin IRAPB may 
play an important role in the recurrence mechanism of AF in 
the No-Test group.
Clinical significance of non-PV foci
APBs that trigger AF frequently arise from PVs,20 and cardiac 
autonomic nerves mainly connect to the heart along the PV an-
tral area.4,21,22 Therefore, bi-antral PV isolation is effective for the 
elimination of PV triggers,23,24 cardiac autonomic denervation,25 
and substrate modification. However, PV isolation may not be 
sufficient to control AF due to the presence of non-PV foci or 
atrial substrate remodeling, particularly in patients with PeAF.26,27 
Clinically, complex fractionated atrial electrograms (CFAEs) are 
known to play a role in maintaining AF28,29 and act as a target for 
AF catheter ablation.29,30 Verma, et al.31 considered CFAE abla-
tion to be a non-PV substrate and a trigger of ablation, and Le-
mery, et al.32 co-localized the area of CFAE and cardiac auto-
nomic ganglionated plexi by nerve stimulation. However, CFAE 
includes both the active driver of AF and passive wave breakers, 
and CFAE-guided AF ablation carries the risk of unnecessary 
cardiac tissue damage. In this study, we ablated non-PV foci 
targeting post-cardioversion IRAPBs and demonstrated a better 
clinical outcome.
Mapping and ablation technique for non-PV foci
We previously reported that an excessively long ablation dura-
tion for substrate modification results in a poor clinical out-
come.33,34 Therefore, limited and sophisticated ablation for non-
Table 4. Characteristics Comparing IRAPB Provocation/Ablation Group vs. No-Test Group
Variables All (n=200) Provocation of IRAPB (n=100) No test (n=100) p value
Male, n (%) 153 (76.5) 76 (76.0) 77 (77.0) 0.868
Age (yrs) 57.4±11.1 57.0±11.0 57.9±11.2 0.551
PAF, n (%) 134 (67.0) 70 (70.0) 64 (64.0) 0.369
BMI (kg/m2) 24.9±3.9 24.5±2.8 25.3±4.7 0.233
CHADS2 score, n (%) 0.8±1.0 0.8±0.9 0.9±1.0 0.309
Congestive heart failure 6 (3.0) 2 (2.0) 4 (4.0) 0.410
Hypertension 92 (46.0) 43 (43.0) 49 (49.0) 0.397
Age ≥75 yrs 4 (2.0) 2 (2.0) 2 (2.0) 1.000
Diabetes 28 (14.0) 11 (11.0) 17 (17.0) 0.223
Stroke/TIA 18 (9.0) 9 (9.0) 9 (9.0) 1.000
Sinus node dysfunction, n (%) 10 (5.0) 7 (7.0) 3 (3.0) 0.196
LA diameter (mm) 40.2±4.8 39.8±4.6 40.7±5.0 0.187
LA volume index (mL/m2) 32.0±10.2 30.8±10.1 33.2±10.2 0.105
LV EF (%) 63.6±7.7 64.2±7.5 63.0±7.9 0.275
E/Em 9.7±4.3 9.2±3.2 10.2±5.1 0.107
RFCA procedural parameters
Procedure time (min) 180.9±34.5 182.5±34.2 179.4±34.8 0.540
Ablation time (sec) 4803.5±1286.4 4822.8±1384.4 4786.4±1199.7 0.848
Ablation strategy, n (BDB rate, %)
PVI 200 (100.0) 100 (100.0) 100 (100.0) >0.999
CTI block 192 (100.0) 94 (100.0) 98 (100.0) 0.155
Roof line 66 (97.0) 30 (100.0) 36 (94.4) 0.369
Posterior-inferior line 51 (71.9) 29 (66.7) 22 (76.5) 0.258
Anterior linear line 53 (67.9) 26 (57.1) 27 (78.6) 0.873
Procedure-related complications, n (%) 7 (3.5) 4 (4.0) 3 (3.0) 0.702
Hemopericardium 4 (2.0) 1 (1.0) 3 (3.0) 0.315
Mild PV stenosis 1 (0.5) 1 (1.0) 0 (0.0) 0.319
Groin hematoma 2 (1.0) 2 (2.0) 0 (0.0) 0.157
Follow-up duration (months) 18.0±6.6 17.9±6.9 18.2±6.4 0.694
Early recurrence rates (%) 30.5 19.0 42.0 <0.001
Clinical recurrence rates (%) 21.5 15.0 28.0 0.025
BMI, body mass index; E/Em, ratio of early mitral inflow peak velocity and Doppler-derived early diastolic mitral annular velocity; IRAPB, immediate recurrence 
of atrial premature beats after cardioversion; LA, left atrium; LV EF, left ventricular ejection fraction; PAF, paroxysmal atrial fibrillation; PV, pulmonary vein; PVI, 
pulmonary vein isolation; TIA, transient ischemic attack; BDB, bidirectional block; RFCA, radiofrequency catheter ablation; CTI, cavotricuspid isthmus.
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PV foci based on post-procedural IRAPB might be beneficial for 
a better clinical outcome. However, detection and ablation of 
non-PV foci are not simple. We targeted non-PV foci immedi-
ately after cardioversion under isoproterenol (5 μg/min) infu-
sion. As we adhered to the linear ablation strategy, including 
the anterior line10 in patients with PeAF, re-initiation of AF was 
uncommon (8%) after cardioversion and cessation of isoproter-
enol infusion, and most non-PV foci remained as frequent APBs. 
We were able to map those non-PV IRAPBs based on the areas 
defined by linear ablation lines.11 Quick and limited 3D activa-
tion mapping utilizing a multi-electrode catheter was useful for 
accurate mapping and limited ablation of frequent non-PV–ori-
gin APBs in certain patients. We mapped and ablated IRAPBs 
during the isoproterenol cooling-down period until no APBs 
appeared.
Limitations
The patients included in this study were a highly selective group 
referred for RFCA, and the number of patients was limited. As 
this was a retrospective single-center study, there might have 
been a selection bias, despite comparing two groups matched 
for age, sex, and AF type. Considering that most IRAPBs were 
mapped and ablated within 10 minutes after stopping isopro-
terenol infusion, infrequent IRAPBs, multi-focal APBs, and cat-
echolamine-insensitive APBs may not have been eliminated in 
this study protocol. In addition, we did not challenge isoproter-
enol again after IRAPB ablation.
Conclusion
The patients who showed post-procedural IRAPB under isopro-
terenol had a clearly higher clinical recurrence rate of AF. How-
ever, careful mapping and ablation for post-procedural IRAPB 
safely resulted in a better clinical outcome without requiring a 
longer procedure time compared to those who completed the 
procedure without an induction test. Therefore, a future pro-
spective study with a larger number of patients is warranted to 
determine whether routine IRAPB provocation facilitates an 
improved clinical outcome of AF catheter ablation.
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